Please assess the completion status of the following clinical trial:

Trial Title: Investigate Safety, Pharmacokinetics and Pharmacodynamics of GSK2118436 & GSK1120212

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Key Inclusion Criteria:~* Capable of given written informed consent, which includes compliance with the requirements and restrictions listed in the consent form.~* Male or female age 18 years or greater; able to swallow and retain oral medication.~* BRAF mutation positive melanoma or colorectal cancer; other BRAF mutation positive tumor types may be considered.~* Measurable disease according to RECIST version 1.1.~* Eastern Cooperative Oncology Group Performance Status of 0 or 1 for Parts A and B. Subjects with Eastern Cooperative Oncology Group Performance Status of 2 or less may be entered into Part C with approval of medical monitor.~* Agree to contraception requirements.~* Calcium phosphorus product less than 4.0mmol2/L2.~* Adequate organ system function.~Key Exclusion Criteria:~* Currently receiving cancer therapy (chemotherapy, radiation therapy, immunotherapy, or biologic therapy).~* Part A and Part B: Prior exposure to BRAF or MEK inhibitors unless approved by the GSK Medical Monitor.~* Part C: Prior exposure to BRAF or MEK inhibitors. Prior anti-cancer therapy in the metastatic setting, with the exception of up to one regimen of chemotherapy and/or interleukin-2 (IL-2).~* Part D: Prior exposure to BRAF inhibitors. A washout period of 6 weeks is required for ipilimumab.~* Received an investigational anti-cancer drug within 4 weeks or 5 half-lives (whichever is shorter) of study drug administration--- at least 14 days must have passed between the last dose of prior investigational anti-cancer drug and the first dose of study drug.~* Current use of a prohibited medication or requires any of these medications during treatment with study drug.~* Current use of therapeutic warfarin.~* Any major surgery, radiotherapy, or immunotherapy within the last 4 weeks. Limited radiotherapy within the last 2 weeks.~* Chemotherapy regimens with delayed toxicity within the last 4 weeks. Chemotherapy regimens given continuously or on a weekly basis with limited potential for delayed toxicity within the last 2 weeks.~* Unresolved toxicity greater than National Cancer Institute-Common Terminology Criteria for Adverse Events version 4 Grade 1 from previous anti-cancer therapy except alopecia.~* History of retinal vein occlusion, central serous retinopathy or glaucoma.~* Predisposing factors to retinal vein occlusion including uncontrolled hypertension, uncontrolled diabetes, uncontrolled hyperlipidemia, and coagulopathy.~* Visible retinal pathology as assessed by ophthalmologic exam that is considered a risk factor for retinal vein occlusion or central serous retinopathy.~* Intraocular pressure greater than 21mm Hg as measured by tonography.~* Glaucoma diagnosed within one month prior to study Day 1.~* Presence of active gastrointestinal disease or other condition that will interfere significantly with the absorption, distribution, metabolism or excretion of drugs.~* Known human immunodeficiency virus, Hepatitis B or Hepatitis C infection.~* Primary malignancy of the central nervous system.~* Untreated or symptomatic brain metastasis, leptomeningeal disease or spinal cord compression. Subjects who are on a stable dose of corticosteroids for more than 1 month or off corticosteroids for 2 weeks can be enrolled with approval of medical monitor. Subjects are not permitted to receive enzyme-inducing anti-epileptic drugs.~* Subjects with brain metastases are excluded, unless~  a. All known lesions must be previously treated with surgery or stereotactic radiosurgery, and- b. Brain lesion(s), if still present, must be confirmed stable (i.e. no increase in lesion size) for ≥90 days prior to first dose on study (must be documented with two consecutive MRI or CT scans using contrast), and c. Asymptomatic with no corticosteroids requirement for ≥ 30 days prior to first dose on study, and d. No enzyme-inducing anticonvulsants for ≥ 30 days prior to first dose on study.~* History of alcohol or drug abuse within 6 months prior to screening.~* Psychological, familial, sociological or geographical conditions that do not permit compliance with the protocol.~* QTc interval greater than or equal to 480msecs.~* History of acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting within the past 24 weeks.~* Class II, III, or IV heart failure as defined by the New York Heart Association functional classification system.~* Abnormal cardiac valve morphology (subjects with minimal abnormalities can be entered on study with approval from the medical monitor.~* Treatment refractory hypertension defined as a blood pressure of systolic\> 140 mmHg and/or diastolic \> 90 mm Hg which cannot be controlled by anti-hypertensive therapy~* Patients with intra-cardiac defibrillators or permanent pacemakers.~* Cardiac metastases~* Known immediate or delayed hypersensitivity reaction or idiosyncrasy to drugs chemically related to the study drugs or excipients.~* Pregnant or lactating female.~* Unwillingness or inability to follow the procedures required in the protocol.~* Uncontrolled diabetes, hypertension or other medical conditions that may interfere with assessment of toxicity.~* Subjects with known glucose 6 phosphate dehydrogenase deficiency.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm Part A (Type: EXPERIMENTAL): Day 1: GSK2118436 75mg; Day 2 through Day 16: GSK1120212 2mg; Day 15: GSK2118436 75mg +GSK1120212 2mg Drug-drug interaction
- Arm Part B (Type: EXPERIMENTAL): GSK2118436 + GSK1120212 Dose escalation to a maximum tolerated combination dose
- Arm Part C (Type: EXPERIMENTAL): GSK2118436 + GSK1120212 cohort expansion for safety and efficacy

Based on this trial design, predict the completion outcome and termination type (if applicable).